CENTOCOR, INC.
🇺🇸United States
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
Phase 3
Completed
- Conditions
- Angioplasty, Transluminal, Percutaneous CoronaryAngina, Unstable
- Interventions
- Drug: AbciximabDrug: Placebo
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 2038
- Registration Number
- NCT00269893
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT00269854
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
Phase 3
Completed
- Conditions
- Angioplasty, Transluminal, Percutaneous CoronaryAngina, Unstable
- Interventions
- Drug: PlaceboDrug: Abciximab
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 1265
- Registration Number
- NCT00269906
Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 428
- Registration Number
- NCT00269867
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
Phase 2
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: CNTO 1275 63 mgDrug: Placebo
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT00267956
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- Biological: golimumabBiological: Placebo; golimumab
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT00265096
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Phase 3
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: golimumabBiological: Golimumab (CNTO 148); placebo
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT00265083
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00265122
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Phase 1
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: CNTO 328
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT00265135
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Golimumab 50 mgDrug: Golimumab 100 mgDrug: MethotrexateDrug: Placebo capsulesDrug: Placebo injection
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 444
- Registration Number
- NCT00264550
© Copyright 2025. All Rights Reserved by MedPath